ImmunityBio Revenue Increases 700% Year Over Year
ImmunityBio (NASDAQ:IBRX) closed at $5.52, up 39.75% after premarket updates showed significant Anktiva revenue growth, positive trial data, and new ...
Tag: ImmunityBio
News Summarized. Time Saved. Bite-sized news briefs for busy people. No fluff, just facts.